StockData
Passage BIO, Inc. logo

Passage BIO, Inc. (PASG) stock

PASGNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 5/30
$4.13−0.08 (-2.01%)

Close on Nov 18, 2026Market cap $13.31MP/E –Yield –

Passage BIO free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

For fiscal 2024 it was -$47.99M.

Annual free cash flow

PeriodPeriod endValueChange
FY2024Dec 31, 2024-$47.99M–

More Passage BIO figures

See a number that looks wrong?